Study on anti-HIV-1 activities of composite extract from salvia yunnanensis.
- Author:
Zong-gen PENG
1
;
De-hua QIN
;
Li TENG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Anti-HIV Agents; pharmacology; therapeutic use; Cell Line; Cells, Cultured; Drugs, Chinese Herbal; pharmacology; therapeutic use; Female; HIV Infections; drug therapy; virology; HIV-1; drug effects; enzymology; physiology; Humans; Leukocytes, Mononuclear; virology; Male; Mice; Mice, Inbred BALB C; Salvia; chemistry; T-Lymphocytes; virology; Viral Proteins; antagonists & inhibitors; Virus Replication; drug effects
- From: Chinese Journal of Integrated Traditional and Western Medicine 2008;28(8):711-715
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore and evaluate the activities of composite extract from Salvia Yunnanensis and in cell cultures (DS-MEF) for inhibition of human immuno-deficiency virus type 1 (HIV-1) in vitro and in cell cultures.
METHODSThe inhibitory activity of DS-MEF on HIV-1 reverse transcriptase (RT), protease (PR) and integrase (IN) were detected in vitro with radionuclide 3H incorporation, fluorescence assay and enzyme-linked immunosorbent assay respectively. The human T-lymphocyte MT-4 cell line, human T-lymphocyte H 9 cell line chronically infected with HIV-1 IIIB, and the fresh peripheral blood mononuclear cell (PBMC) of healthy persons as well as the laboratory passed HIV-1 IIIB and the clinically isolated HIV-1 AZT sensitive 018a or resistant 018c infected cell cultures were used for evaluating the cytotoxicities and inhibitory activities of DS-MEF on HIV-1 P 24 antigen. The acute toxicities of DS-MEF on KM mice were determined by gastric gavages and intraperitoneal injections with various dosages.
RESULTSThe IC50 of DS-MEF for inhibiting HIV-1 IN, RT and PR were 2.59 +/- 0.50 mg/L, 27.39 +/- 11.18 mg/L and 9.38 +/- 2.45 mg/L respectively. In MT-4 cell cultures infected with HIV-1 III, TC50 were 13.19 +/- 6.07 mg/L, IC50 and SI of anti-HIV-1 activity were 0.224 +/- 0.163 mg/L and 58.7; in chronically infected H 9 cell cultures, TC50 were 18.11 +/- 9.84 mg/L, IC50 on HIV-1 P 24 antigen and SI were l7.230 +/- 21.114 mg/L and 1.1 respectively; TC50 in HIV-1 infected PBMC cultures were 288.70 +/- 0.08 mg/L; IC50 on AZT sensitive HIV-1 018a: 26.42 +/- 11.16 mg/L, and SI: 10.9; On AZT resistant HIV-1 018c, IC50: 27.87 +/-5.35 mg/L, and SI: 10.4. Moreover, DS-MEF showed synergistic effect with AZT or nevirapine (NVP) on HIV-1 IIIB in MT-4 cell cultures, the respective combination index was 0.78 or 0.67. DS-MEF showed no acute toxicity in KM mice with the dosage up to 20 g/kg via gastrogavage, and the 50% lethal dose (LD50) via intraperitoneal injection was 1.18 g/kg.
CONCLUSIONDS-MEF is a promising anti- HIV-1 agent with low toxicity in mice and possesses multi-targets and effective activities.
